Header Logo

Connection

C OSBORNE to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications C OSBORNE has written about Breast Neoplasms.
C OSBORNE
Connection Strength
7.960
Breast Neoplasms
  1. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015; 66:111-28.
    View in: PubMed
    Score: 0.181
  2. Circulating tumor DNA--ready for prime time? N Engl J Med. 2013 Mar 28; 368(13):1249-50.
    View in: PubMed
    Score: 0.160
  3. Breast Cancer: Blocking both driver and escape pathways improves outcomes. Nat Rev Clin Oncol. 2012 Feb 14; 9(3):133-4.
    View in: PubMed
    Score: 0.148
  4. Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting. Oncology (Williston Park). 2011 Dec; 25(14):1422-4, 1426.
    View in: PubMed
    Score: 0.146
  5. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011 Mar 01; 17(5):1147-59.
    View in: PubMed
    Score: 0.138
  6. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233-47.
    View in: PubMed
    Score: 0.137
  7. Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
    View in: PubMed
    Score: 0.098
  8. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20; 23(33):8313-21.
    View in: PubMed
    Score: 0.096
  9. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol. 2005 Nov; 56 Suppl 1:10-20.
    View in: PubMed
    Score: 0.096
  10. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast. 2005 Dec; 14(6):458-65.
    View in: PubMed
    Score: 0.096
  11. Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res. 2005; 7(5):205-11.
    View in: PubMed
    Score: 0.094
  12. Aromatase inhibitors: future directions. J Steroid Biochem Mol Biol. 2005 May; 95(1-5):183-7.
    View in: PubMed
    Score: 0.093
  13. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005 Jul 20; 23(21):4687-94.
    View in: PubMed
    Score: 0.092
  14. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol. 2005 Mar 10; 23(8):1616-22.
    View in: PubMed
    Score: 0.092
  15. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):865s-70s.
    View in: PubMed
    Score: 0.091
  16. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 01; 22(9):1605-13.
    View in: PubMed
    Score: 0.087
  17. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004 Mar; 90 Suppl 1:S2-6.
    View in: PubMed
    Score: 0.086
  18. Role of molecular and genetic markers in breast cancer treatment decisions. J Clin Oncol. 2003 Dec 01; 21(23 Suppl):285s-287s.
    View in: PubMed
    Score: 0.084
  19. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003 Dec; 12(6):362-7.
    View in: PubMed
    Score: 0.084
  20. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
    View in: PubMed
    Score: 0.080
  21. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):447S-54S.
    View in: PubMed
    Score: 0.079
  22. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15; 20(16):3386-95.
    View in: PubMed
    Score: 0.077
  23. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s.
    View in: PubMed
    Score: 0.073
  24. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
    View in: PubMed
    Score: 0.068
  25. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer. 2000 Mar 20; 89(2):111-7.
    View in: PubMed
    Score: 0.065
  26. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009 Aug 18; 106(33):13820-5.
    View in: PubMed
    Score: 0.062
  27. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol. 1999 Aug; 17(8):2334-40.
    View in: PubMed
    Score: 0.062
  28. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Relat Cancer. 1999 Jun; 6(2):271-6.
    View in: PubMed
    Score: 0.062
  29. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26; 339(22):1609-18.
    View in: PubMed
    Score: 0.059
  30. Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin Cancer Res. 1998 May; 4(5):1263-6.
    View in: PubMed
    Score: 0.057
  31. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat. 2009 Mar; 114(2):287-99.
    View in: PubMed
    Score: 0.057
  32. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998 Mar; 16(3):994-9.
    View in: PubMed
    Score: 0.056
  33. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res. 1998 Jan; 4(1):7-12.
    View in: PubMed
    Score: 0.056
  34. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998; 51(3):227-38.
    View in: PubMed
    Score: 0.056
  35. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol. 1997 Jul; 15(7):2494-501.
    View in: PubMed
    Score: 0.054
  36. Oestrogen receptors and breast cancer. BMJ. 1997 Jun 28; 314(7098):1843-4.
    View in: PubMed
    Score: 0.054
  37. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol. 1997 May; 15(5):1916-22.
    View in: PubMed
    Score: 0.053
  38. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997 May; 44(1):65-74.
    View in: PubMed
    Score: 0.053
  39. Aromatase inhibitors in the treatment of advanced breast cancer. Introduction. Semin Oncol. 1996 Aug; 23(4 Suppl 9):1.
    View in: PubMed
    Score: 0.051
  40. Targeting the epidermal growth factor receptor in breast cancer cell lines with a recombinant ligand fusion toxin (DAB389EGF). Cancer J Sci Am. 1996 May-Jun; 2(3):175-80.
    View in: PubMed
    Score: 0.050
  41. Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci. 1996 Apr 30; 784:325-35.
    View in: PubMed
    Score: 0.050
  42. Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996 Jan; 14(1):46-51.
    View in: PubMed
    Score: 0.049
  43. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst. 1995 May 17; 87(10):746-50.
    View in: PubMed
    Score: 0.046
  44. Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. Breast Cancer Res. 2015 Jan 09; 17:3.
    View in: PubMed
    Score: 0.045
  45. Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ. 1994 Dec; 5(12):1275-82.
    View in: PubMed
    Score: 0.045
  46. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct; 12(10):2078-85.
    View in: PubMed
    Score: 0.045
  47. Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee. Cancer. 1994 Aug 01; 74(3 Suppl):1135-8.
    View in: PubMed
    Score: 0.044
  48. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994 May 04; 86(9):705-12.
    View in: PubMed
    Score: 0.043
  49. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
    View in: PubMed
    Score: 0.043
  50. Translational research in the San Antonio breast cancer SPORE. Breast Cancer Res Treat. 1994; 32(1):1-4.
    View in: PubMed
    Score: 0.042
  51. Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat. 1994; 32(1):105-12.
    View in: PubMed
    Score: 0.042
  52. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):13-8.
    View in: PubMed
    Score: 0.042
  53. Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994; 32(1):49-55.
    View in: PubMed
    Score: 0.042
  54. Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71.
    View in: PubMed
    Score: 0.042
  55. Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat. 1994; 32(1):97-103.
    View in: PubMed
    Score: 0.042
  56. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. Ann Oncol. 1994 Jan; 5(1):43-7.
    View in: PubMed
    Score: 0.042
  57. Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism. J Steroid Biochem Mol Biol. 1993 Dec; 47(1-6):83-9.
    View in: PubMed
    Score: 0.042
  58. Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum. 1993 Oct; 20(9):1415-9.
    View in: PubMed
    Score: 0.042
  59. One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study. J Clin Oncol. 1993 Sep; 11(9):1710-6.
    View in: PubMed
    Score: 0.041
  60. A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 2013 Jan; 24(1):47-53.
    View in: PubMed
    Score: 0.038
  61. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 1992 Jul 01; 52(13):3636-41.
    View in: PubMed
    Score: 0.038
  62. Prognostic factors in breast cancer. Semin Oncol. 1992 Jun; 19(3):244-53.
    View in: PubMed
    Score: 0.038
  63. Prognostic factors for breast cancer: have they met their promise? J Clin Oncol. 1992 May; 10(5):679-82.
    View in: PubMed
    Score: 0.038
  64. Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol. 1992 Feb; 10(2):304-10.
    View in: PubMed
    Score: 0.037
  65. Polypeptide growth factors: their potential value in the management of breast cancer patients. Cancer Treat Res. 1992; 60:315-29.
    View in: PubMed
    Score: 0.037
  66. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node-positive adjuvant CMFVP breast cancer data base: a pilot study. Breast Cancer Res Treat. 1992; 22(3):273-84.
    View in: PubMed
    Score: 0.037
  67. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992; 24(2):85-95.
    View in: PubMed
    Score: 0.037
  68. Dose intensity as a therapeutic strategy in breast cancer. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S11-4.
    View in: PubMed
    Score: 0.037
  69. Hematopoietic growth factors in breast cancer--overview. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S1-2.
    View in: PubMed
    Score: 0.037
  70. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29; 9(1):16-32.
    View in: PubMed
    Score: 0.037
  71. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst. 1991 Oct 16; 83(20):1477-82.
    View in: PubMed
    Score: 0.036
  72. A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer. 1991 Oct 15; 68(8):1694-5.
    View in: PubMed
    Score: 0.036
  73. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 07; 83(15):1077-84.
    View in: PubMed
    Score: 0.036
  74. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clin Cancer Res. 2011 Sep 01; 17(17):5559-61.
    View in: PubMed
    Score: 0.036
  75. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol. 1991 Jul; 9(7):1283-97.
    View in: PubMed
    Score: 0.036
  76. Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1991 Feb; 9(1):87-8.
    View in: PubMed
    Score: 0.035
  77. Growth factors as mediators of estrogen/antiestrogen action in human breast cancer cells. Cancer Treat Res. 1991; 53:289-304.
    View in: PubMed
    Score: 0.034
  78. Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol. 1990 Dec 20; 37(6):805-9.
    View in: PubMed
    Score: 0.034
  79. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010 Dec 15; 16(24):6169-76.
    View in: PubMed
    Score: 0.034
  80. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010 Nov 17; 102(22):1706-15.
    View in: PubMed
    Score: 0.034
  81. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010 Jul; 134(7):e48-72.
    View in: PubMed
    Score: 0.033
  82. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 06; 134(6):907-22.
    View in: PubMed
    Score: 0.033
  83. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010 Jun 01; 28(16):2784-95.
    View in: PubMed
    Score: 0.033
  84. Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov; 124(2):433-9.
    View in: PubMed
    Score: 0.033
  85. Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat. 1990 Jan; 15(1):3-11.
    View in: PubMed
    Score: 0.032
  86. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-2063.
    View in: PubMed
    Score: 0.032
  87. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010 Jan; 11(1):55-65.
    View in: PubMed
    Score: 0.032
  88. Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):641-52.
    View in: PubMed
    Score: 0.032
  89. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989 Nov; 84(5):1418-23.
    View in: PubMed
    Score: 0.032
  90. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol. 1989 Nov; 3(11):1701-9.
    View in: PubMed
    Score: 0.032
  91. Megestrol acetate in breast cancer--a panel discussion. Breast Cancer Res Treat. 1989 Oct; 14(1):33-8.
    View in: PubMed
    Score: 0.031
  92. DNA flow cytometry in early breast cancer: a step in the right direction. J Natl Cancer Inst. 1989 Sep 20; 81(18):1344-5.
    View in: PubMed
    Score: 0.031
  93. Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol. 2009 Oct 20; 27(30):4973-9.
    View in: PubMed
    Score: 0.031
  94. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66.
    View in: PubMed
    Score: 0.031
  95. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol. 1989 Jun; 7(6):710-7.
    View in: PubMed
    Score: 0.031
  96. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol. 2009 May 01; 27(13):2157-62.
    View in: PubMed
    Score: 0.030
  97. Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Mar; 13(2):97-115.
    View in: PubMed
    Score: 0.030
  98. Pain control in breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Jan; 13(1):5-15.
    View in: PubMed
    Score: 0.030
  99. Cell proliferative indices and DNA content as prognostic factors in primary breast cancer. Horm Res. 1989; 32 Suppl 1:238-41.
    View in: PubMed
    Score: 0.030
  100. Adjuvant treatment of node-negative breast cancer. Tex Med. 1989 Jan; 85(1):32-6.
    View in: PubMed
    Score: 0.030
  101. Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol. 1988 Nov; 2(11):1064-9.
    View in: PubMed
    Score: 0.030
  102. Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res. 1988 Jul 15; 48(14):3898-904.
    View in: PubMed
    Score: 0.029
  103. Secreted growth factors from estrogen receptor-negative human breast cancer do not support growth of estrogen receptor-positive breast cancer in the nude mouse model. Breast Cancer Res Treat. 1988 Jul; 11(3):211-9.
    View in: PubMed
    Score: 0.029
  104. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res. 2008 Feb 01; 68(3):826-33.
    View in: PubMed
    Score: 0.028
  105. Endocrine therapy of human breast cancer grown in nude mice. Breast Cancer Res Treat. 1987 Dec; 10(3):229-42.
    View in: PubMed
    Score: 0.028
  106. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol. 1987 Aug; 23(8):1189-96.
    View in: PubMed
    Score: 0.027
  107. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185). Am J Clin Oncol. 2007 Apr; 30(2):113-25.
    View in: PubMed
    Score: 0.026
  108. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20; 25(6):656-61.
    View in: PubMed
    Score: 0.026
  109. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987; 9(2):111-21.
    View in: PubMed
    Score: 0.026
  110. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell. 2006 Dec; 10(6):487-99.
    View in: PubMed
    Score: 0.026
  111. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006 Oct 01; 24(28):4611-9.
    View in: PubMed
    Score: 0.026
  112. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15; 66(16):8266-73.
    View in: PubMed
    Score: 0.025
  113. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006 Aug; 98(3):315-27.
    View in: PubMed
    Score: 0.025
  114. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006 Feb; 95(3):229-33.
    View in: PubMed
    Score: 0.024
  115. Adjuvant chemotherapy. CA Cancer J Clin. 1986 Jan-Feb; 36(1):59-60.
    View in: PubMed
    Score: 0.024
  116. Adjuvant therapy of breast cancer: Southwest Oncology Group studies. NCI Monogr. 1986; (1):71-4.
    View in: PubMed
    Score: 0.024
  117. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 2005 Dec; 94(3):279-84.
    View in: PubMed
    Score: 0.024
  118. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat. 2005 Dec; 94(3):205-11.
    View in: PubMed
    Score: 0.024
  119. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat. 2006 Jan; 95(1):7-12.
    View in: PubMed
    Score: 0.024
  120. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005 Oct 20; 23(30):7721-35.
    View in: PubMed
    Score: 0.024
  121. Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor. Mol Endocrinol. 2006 Feb; 20(2):311-20.
    View in: PubMed
    Score: 0.024
  122. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005 Sep 07; 97(17):1254-61.
    View in: PubMed
    Score: 0.024
  123. Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol. 1985 Sep; 12(3):317-26.
    View in: PubMed
    Score: 0.024
  124. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 01; 23(25):5973-82.
    View in: PubMed
    Score: 0.024
  125. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15; 104(2):236-9.
    View in: PubMed
    Score: 0.024
  126. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer. 2005 Jul; 12 Suppl 1:S113-7.
    View in: PubMed
    Score: 0.023
  127. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10; 23(11):2469-76.
    View in: PubMed
    Score: 0.023
  128. Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. Breast Cancer Res Treat. 2005 Mar; 90(1):1-3.
    View in: PubMed
    Score: 0.023
  129. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol. 2005 Feb 20; 23(6):1169-77.
    View in: PubMed
    Score: 0.023
  130. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
    View in: PubMed
    Score: 0.023
  131. Insights into the role of progesterone receptors in breast cancer. J Clin Oncol. 2005 Feb 01; 23(4):931-2; author reply 932-3.
    View in: PubMed
    Score: 0.023
  132. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985 Feb; 45(2):584-90.
    View in: PubMed
    Score: 0.023
  133. Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 2):861s-4s.
    View in: PubMed
    Score: 0.023
  134. Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay. Breast Cancer Res Treat. 1985; 6(3):229-35.
    View in: PubMed
    Score: 0.023
  135. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol. 2005 Jan 01; 23(1):24-9.
    View in: PubMed
    Score: 0.022
  136. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
    View in: PubMed
    Score: 0.022
  137. Hormone receptors in the management of breast cancer. Tex Med. 1984 Nov; 80(11):30-2.
    View in: PubMed
    Score: 0.022
  138. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004 Sep 01; 10(17):5670-6.
    View in: PubMed
    Score: 0.022
  139. Perturbation by insulin of human breast cancer cell cycle kinetics. Cancer Res. 1984 Aug; 44(8):3570-5.
    View in: PubMed
    Score: 0.022
  140. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004 Jun 16; 96(12):926-35.
    View in: PubMed
    Score: 0.022
  141. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res. 1984 Apr; 44(4):1433-9.
    View in: PubMed
    Score: 0.022
  142. Bisantrene, an active drug in patients with advanced breast cancer. Cancer Treat Rep. 1984 Feb; 68(2):357-60.
    View in: PubMed
    Score: 0.021
  143. Spreading the word, but not too thinly. Lancet. 2004 Jan 10; 363(9403):165-6.
    View in: PubMed
    Score: 0.021
  144. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 2):331S-6S.
    View in: PubMed
    Score: 0.021
  145. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst. 2003 Dec 17; 95(24):1825-33.
    View in: PubMed
    Score: 0.021
  146. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003 Aug 02; 362(9381):362-9.
    View in: PubMed
    Score: 0.021
  147. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 1983 Aug; 43(8):3583-5.
    View in: PubMed
    Score: 0.021
  148. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003 Jul 15; 98(2):229-38.
    View in: PubMed
    Score: 0.020
  149. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 03; 349(1):17-26.
    View in: PubMed
    Score: 0.020
  150. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer. 2003 Jun; 39(9):1228-33.
    View in: PubMed
    Score: 0.020
  151. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003 May 15; 21(10):1973-9.
    View in: PubMed
    Score: 0.020
  152. Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 2003 May 15; 63(10):2434-9.
    View in: PubMed
    Score: 0.020
  153. Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Mol Endocrinol. 2003 Aug; 17(8):1543-54.
    View in: PubMed
    Score: 0.020
  154. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003 May; 79(2):207-11.
    View in: PubMed
    Score: 0.020
  155. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
    View in: PubMed
    Score: 0.020
  156. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Cancer. 2003 Jan 01; 97(1):21-9.
    View in: PubMed
    Score: 0.020
  157. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res. 2003 Jan; 9(1 Pt 2):443S-6S.
    View in: PubMed
    Score: 0.020
  158. Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. Mol Ther. 2002 Dec; 6(6):783-92.
    View in: PubMed
    Score: 0.020
  159. Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene. 2002 Oct 31; 21(50):7680-9.
    View in: PubMed
    Score: 0.019
  160. Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement. Clin Cancer Res. 2001 Dec; 7(12 Suppl):4335s-4337s; discussion 4411s-4412s.
    View in: PubMed
    Score: 0.018
  161. Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res. 2001 Aug 01; 61(15):5771-7.
    View in: PubMed
    Score: 0.018
  162. Loss of heterozygosity events impeding breast cancer metastasis contain the MTA1 gene. Cancer Res. 2001 May 01; 61(9):3578-80.
    View in: PubMed
    Score: 0.018
  163. Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. J Clin Invest. 1981 Apr; 67(4):943-51.
    View in: PubMed
    Score: 0.017
  164. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res. 2001 Mar 01; 61(5):2320-7.
    View in: PubMed
    Score: 0.017
  165. High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer. 2001 Feb; 84(4):493-8.
    View in: PubMed
    Score: 0.017
  166. Estrogen receptor, a marker for human breast cancer differentiation and patient prognosis. Adv Exp Med Biol. 1981; 138:377-85.
    View in: PubMed
    Score: 0.017
  167. Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat. 1981; 1(2):121-3.
    View in: PubMed
    Score: 0.017
  168. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15; 46(12 Suppl):2884-8.
    View in: PubMed
    Score: 0.017
  169. Modern approaches to the treatment of breast cancer. Blood. 1980 Nov; 56(5):745-52.
    View in: PubMed
    Score: 0.017
  170. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000 Sep; 18(17):3172-86.
    View in: PubMed
    Score: 0.017
  171. HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clin Cancer Res. 2000 Sep; 6(9):3788-96.
    View in: PubMed
    Score: 0.017
  172. Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res. 1980 Jul; 40(7):2361-6.
    View in: PubMed
    Score: 0.017
  173. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res. 2000 Feb; 6(2):616-21.
    View in: PubMed
    Score: 0.016
  174. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol. 1999 Oct; 17(10):3058-63.
    View in: PubMed
    Score: 0.016
  175. Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.
    View in: PubMed
    Score: 0.016
  176. Direct inhibition of growth and antagonism of insulin action by glucocorticoids in human breast cancer cells in culture. Cancer Res. 1979 Jul; 39(7 Pt 1):2422-8.
    View in: PubMed
    Score: 0.015
  177. Therapy for cancer of the breast. Current status of steroid hormone receptors. West J Med. 1979 May; 130(5):401-7.
    View in: PubMed
    Score: 0.015
  178. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol. 1999 May; 13(5):787-96.
    View in: PubMed
    Score: 0.015
  179. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol. 1999 May; 17(5):1442-8.
    View in: PubMed
    Score: 0.015
  180. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999 May; 17(5):1474-81.
    View in: PubMed
    Score: 0.015
  181. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
    View in: PubMed
    Score: 0.015
  182. The use of stero?d hormone receptors in the treatment of human breast cancer: a review. Bull Cancer. 1979; 66(3):203-9.
    View in: PubMed
    Score: 0.015
  183. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. J Clin Oncol. 1998 Nov; 16(11):3486-92.
    View in: PubMed
    Score: 0.015
  184. Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study. Breast Cancer Res Treat. 1998 Sep; 51(2):169-81.
    View in: PubMed
    Score: 0.015
  185. Current use of steroid hormone receptor assays in the treatment of breast cancer. Surg Clin North Am. 1978 Aug; 58(4):777-88.
    View in: PubMed
    Score: 0.015
  186. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998 Jul; 16(7):2382-91.
    View in: PubMed
    Score: 0.014
  187. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998 May 06; 90(9):697-703.
    View in: PubMed
    Score: 0.014
  188. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998 May; 16(5):1655-60.
    View in: PubMed
    Score: 0.014
  189. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998 May; 16(5):1669-76.
    View in: PubMed
    Score: 0.014
  190. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 01; 82(7):1296-302.
    View in: PubMed
    Score: 0.014
  191. Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res. 1978 Jan; 38(1):94-102.
    View in: PubMed
    Score: 0.014
  192. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
    View in: PubMed
    Score: 0.014
  193. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997 Dec 17; 89(24):1874-81.
    View in: PubMed
    Score: 0.014
  194. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res. 1997 Dec 15; 57(24):5505-8.
    View in: PubMed
    Score: 0.014
  195. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res. 1997 Sep 01; 57(17):3723-7.
    View in: PubMed
    Score: 0.014
  196. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer. 1997 Jun; 33(7):1108-13.
    View in: PubMed
    Score: 0.013
  197. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr; 43(2):153-63.
    View in: PubMed
    Score: 0.013
  198. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997 Apr; 3(4):593-600.
    View in: PubMed
    Score: 0.013
  199. Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A. 1976 Dec; 73(12):4536-40.
    View in: PubMed
    Score: 0.013
  200. Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol. 1996 Nov; 14(11):3009-17.
    View in: PubMed
    Score: 0.013
  201. The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
    View in: PubMed
    Score: 0.013
  202. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet. 1996 Apr 20; 347(9008):1066-71.
    View in: PubMed
    Score: 0.012
  203. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996 Mar; 2(3):585-92.
    View in: PubMed
    Score: 0.012
  204. Aberrant subcellular localization of BRCA1 in breast cancer. Science. 1995 Nov 03; 270(5237):789-91.
    View in: PubMed
    Score: 0.012
  205. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
    View in: PubMed
    Score: 0.012
  206. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst. 1995 Aug 16; 87(16):1254-6.
    View in: PubMed
    Score: 0.012
  207. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat. 1995 Mar; 33(3):199-207.
    View in: PubMed
    Score: 0.011
  208. Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancers--a Southwest Oncology Group study. Cancer Res. 1994 Oct 15; 54(20):5357-62.
    View in: PubMed
    Score: 0.011
  209. The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J. 1994 Mar 15; 13(6):1331-40.
    View in: PubMed
    Score: 0.011
  210. Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat. 1994; 32(1):5-12.
    View in: PubMed
    Score: 0.011
  211. Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs. 1994; 12(2):129-32.
    View in: PubMed
    Score: 0.011
  212. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res. 1993 Oct 01; 53(19):4443-8.
    View in: PubMed
    Score: 0.010
  213. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993 Feb 03; 85(3):200-6.
    View in: PubMed
    Score: 0.010
  214. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat. 1993; 26(3):237-46.
    View in: PubMed
    Score: 0.010
  215. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992 Sep; 23(9):974-9.
    View in: PubMed
    Score: 0.010
  216. Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J Clin Oncol. 1992 Jun; 10(6):990-4.
    View in: PubMed
    Score: 0.009
  217. Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol. 1992 Mar; 10(3):428-32.
    View in: PubMed
    Score: 0.009
  218. Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076). J Natl Cancer Inst Monogr. 1992; (11):167-72.
    View in: PubMed
    Score: 0.009
  219. Chemotherapy versus observation in high-risk node-negative breast cancer patients. J Natl Cancer Inst Monogr. 1992; (11):97-104.
    View in: PubMed
    Score: 0.009
  220. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology. 1990 Dec; 127(6):2679-86.
    View in: PubMed
    Score: 0.009
  221. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res. 1989 Nov 15; 49(22):6237-41.
    View in: PubMed
    Score: 0.008
  222. Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene. 1989 Aug; 4(8):979-84.
    View in: PubMed
    Score: 0.008
  223. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989 Feb 23; 320(8):485-90.
    View in: PubMed
    Score: 0.008
  224. Therapy in premenopausal women with advanced, oestrogen positive or/and progesterone positive breast cancer: surgical oophorectomy versus the LHRH analogue, Zoladex. Horm Res. 1989; 32 Suppl 1:221-2.
    View in: PubMed
    Score: 0.007
  225. The role of growth factors in breast cancer. A panel discussion. Breast Cancer Res Treat. 1988 Oct; 12(2):159-66.
    View in: PubMed
    Score: 0.007
  226. Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agents. Eur J Cancer Clin Oncol. 1987 May; 23(5):545-51.
    View in: PubMed
    Score: 0.007
  227. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987 Jan; 5(1):55-61.
    View in: PubMed
    Score: 0.007
  228. The use of restriction fragment polymorphisms to identify the cell line MCF-7. Breast Cancer Res Treat. 1986; 8(1):29-34.
    View in: PubMed
    Score: 0.006
  229. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. J Steroid Biochem. 1985 Dec; 23(6B):1151-4.
    View in: PubMed
    Score: 0.006
  230. Adjuvant chemotherapy for operable breast cancer with positive axillary nodes: a comparison of CMFVP versus L-PAM. World J Surg. 1985 Oct; 9(5):719-22.
    View in: PubMed
    Score: 0.006
  231. Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. World J Surg. 1985 Oct; 9(5):723-7.
    View in: PubMed
    Score: 0.006
  232. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs. 1985; 3(2):149-52.
    View in: PubMed
    Score: 0.006
  233. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984 Oct; 2(10):1102-9.
    View in: PubMed
    Score: 0.006
  234. Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 1983; 3(3):279-85.
    View in: PubMed
    Score: 0.005
  235. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 1983 Jan; 43(1):413-6.
    View in: PubMed
    Score: 0.005
  236. Steroid hormone receptors and carcinoma of the breast. Am J Physiol. 1982 Aug; 243(2):E99-102.
    View in: PubMed
    Score: 0.005
  237. Methods for determining chemosensitivity of MCF-7 cells in double-layer agar culture: labeling index depression and colony count inhibition. Stem Cells (1981). 1982; 2(1):34-44.
    View in: PubMed
    Score: 0.005
  238. Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat. 1981; 1(1):37-41.
    View in: PubMed
    Score: 0.004
  239. Adjuvant therapy for stage II, estrogen receptor negative breast cancer. Breast Cancer Res Treat. 1981; 1(2):131-4.
    View in: PubMed
    Score: 0.004
  240. Potential and problems with growth of breast cancer in a human tumor cloning system. Breast Cancer Res Treat. 1981; 1(2):141-8.
    View in: PubMed
    Score: 0.004
  241. Steroid hormone receptors in the management of human breast cancer. Ann Clin Res. 1980 Oct; 12(5):202-7.
    View in: PubMed
    Score: 0.004
  242. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer. 2000 Aug 15; 89(4):817-25.
    View in: PubMed
    Score: 0.004
  243. Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab. 1980 Jul; 9(2):361-8.
    View in: PubMed
    Score: 0.004
  244. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol. 2000 Mar; 14(3):369-81.
    View in: PubMed
    Score: 0.004
  245. Breast cancer mortality and diet in the United States. Cancer Res. 1979 Sep; 39(9):3628-37.
    View in: PubMed
    Score: 0.004
  246. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2920-5.
    View in: PubMed
    Score: 0.004
  247. Insulin stimulation of fatty acid synthesis in human breast cancer cells. J Natl Cancer Inst. 1977 Jun; 58(6):1591-3.
    View in: PubMed
    Score: 0.003
  248. In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med. 1977 Jan 20; 296(3):154-9.
    View in: PubMed
    Score: 0.003
  249. Resistance to endocrine therapy. A panel discussion. Breast Cancer Res Treat. 1987; 9(3):165-73.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.